🏆 Deal of the Week · CW 1/2024
Vico Therapeutics raised EUR 54 million in a Series B financing round; valuation was not disclosed. The round was announced in January 2024 and backed by a syndicate of seven specialist life-science and growth-equity investors. Proceeds are earmarked to advance the company's lead clinical-stage program, VO659, and to expand its broader pipeline of RNA-modulating therapies for rare neurological diseases.
Vico Therapeutics — key deal facts
| Company | Vico Therapeutics |
| Founded | 2019 |
| Headquarters | Leiden, Netherlands |
| Amount raised | EUR 54M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | Ackermans & van Haaren Droia Ventures EQT life science Eurazeo Kurma Partners Polaris Partners Pureos Bioventures |
| Sectors | Health Care |
Who invested in Vico Therapeutics?
The Series B was supported by Ackermans & van Haaren, Droia Ventures, EQT Life Science, Eurazeo, Kurma Partners, Polaris Partners, and Pureos Bioventures. The investor mix is notable for combining dedicated rare-disease specialists such as Kurma Partners and Pureos Bioventures with large pan-European growth platforms including EQT Life Science and Eurazeo. This breadth of backing reflects strong cross-border institutional conviction in Vico's antisense oligonucleotide approach.
What does Vico Therapeutics do?
Vico Therapeutics is a clinical-stage biotechnology company founded in 2019 by Gail Mandel and Judith van Deutekom, headquartered in Leiden, Netherlands. The company develops antisense oligonucleotide (ASO) RNA-modulating therapies targeting severe neurological disorders, including spinocerebellar ataxia types 1 and 3 and Huntington's disease. Its lead candidate, VO659, is an ASO therapy designed to correct the genetic anomalies underlying polyglutamine diseases, a class of conditions with no approved disease-modifying treatments.
Vico Therapeutics valuation & multiples
No existing multiples analysis was provided for this deal, and valuation remains undisclosed, making EV-based ratio calculations unavailable at this time. Once transaction or comparable-company valuation data becomes available, relevant EV/Sales and EV/EBITDA benchmarks from the Health Care and Biotechnology sector can be applied. Explore Venionaire DealMatrix's Health Care sector multiples pages for current comparable-transaction reference ranges.
Explore the benchmarks: Series B.
Frequently asked questions
How much did Vico Therapeutics raise in its Series B?
Vico Therapeutics raised EUR 54 million in its Series B financing round, announced in January 2024.
What is Vico Therapeutics's valuation?
Vico Therapeutics's valuation was not disclosed in connection with this Series B financing.
Who invested in Vico Therapeutics?
The Series B investors are Ackermans & van Haaren, Droia Ventures, EQT Life Science, Eurazeo, Kurma Partners, Polaris Partners, and Pureos Bioventures.
When was Vico Therapeutics founded and where is it based?
Vico Therapeutics was founded in 2019 and is headquartered in Leiden, Netherlands.
Source: original announcement — read the full report.